ClinicalTrials.gg
TerminatedNCT03656536FIGHT-302Updated Aug 11, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

A Phase 3 interventional study of Pemigatinib and Gemcitabine in Unresectable Cholangiocarcinoma and Metastatic Cholangiocarcinoma, sponsored by Incyte Corporation. Terminated at 215 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pemigatinib in Cholangiocarcinoma — 6 open to participants now, 6 under way, none of them phase 3. pemigatinib · Cholangiocarcinoma.

Enrollment
2nd of 13
167 · median 34
Started
2019
the only one that year
Phase 3
Only one
of the 13
Registered
3rd of 13
by date
Lead sponsor
4 of 13
Incyte Corporation

Among the 13 studies testing pemigatinib in Cholangiocarcinoma, this one is the 2nd largest by enrollment, is the only one that started in 2019, is the only one in phase 3, and was the 3rd registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

6 of the 13 studies testing pemigatinib in Cholangiocarcinoma are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pemigatinib

pemigatinib: first FDA approval 2020 (PEMAZYRE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pemigatinib in Cholangiocarcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

03

Conditions studied

  • Unresectable Cholangiocarcinoma
  • Metastatic Cholangiocarcinoma

Browse trials for

Keywords

  • Cholangiocarcinoma
  • fibroblast growth factor receptor inhibitor
  • FGFR
  • FGFR rearrangement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants at least 18 years of age at the time of signing the form (ICF).
  • or cytologically confirmed cholangiocarcinoma that is previously untreated and considered unresectable and/or (Stage IV per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual).
  • Radiographically measurable or evaluable disease by CT or MRI per v1.1 criteria.
  • performance status 0 to 1.
  • Documented FGFR2 rearrangement.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Received prior anticancer systemic therapy for unresectable and/or disease (not including /neo-adjuvant treatment completed at least 6 months prior to enrollment, and participants that have received treatment for locally advanced disease with trans-arterial chemoembolization or selective internal radiation therapy, if clear evidence of radiological progression is observed before enrollment, or enrolled as of Amendment 6 (or Amendment 5-JP2) and the participant received 1 cycle of gemcitabine plus cisplatin [the start of study drug {Cycle 1 Day 1} must be at least 14 days and ≤ 4 weeks {28 days} from the last dose of gemcitabine plus cisplatin]).
  • B and C.
  • Toxicities related to prior therapy(ies) must be (CTCAE) v5.0 ≤ Grade 1 at the time of screening.
  • Concurrent anticancer therapy, other than the therapies being tested in this study.
  • Participant is a candidate for potentially curative surgery.
  • Current evidence of corneal (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis) or retinal disorder (including but not limited to central serous retinopathy, macular/retinal degeneration, diabetic retinopathy, retinal detachment) as confirmed by ophthalmologic examination.
  • Radiation therapy administered within 4 weeks of enrollment/randomization/first dose of study treatment.
  • Known central nervous system (CNS) metastases or history of uncontrolled seizures.
  • Known additional that is progressing or requires active treatment (exceptions: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy).
  • Laboratory values at screening outside the protocol-defined range.
  • History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (exception: commonly observed calcifications in soft tissues, such as the skin, kidney, tendons or vessels due to injury, disease, and aging, in the absence of systemic mineral imbalance).
  • Significant gastrointestinal disorders that could interfere with absorption, metabolism, or excretion of pemigatinib.
  • Clinically significant or uncontrolled cardiac disease.
  • History or presence of an abnormal , which, in the investigator's opinion, is clinically meaningful.
  • Chronic or current active infectious disease requiring systemic antibiotics or antifungal or antiviral treatment within 2 weeks prior to enrollment (participants with asymptomatic chronic infections on prophylactic treatment are allowed). Note: -positive participants are allowed if all of the following criteria are met: ≥ 300/µL, undetectable viral load, receiving antiretroviral therapy that does not interact with study drug, and no HIV/AIDS-associated opportunistic infection in the last 12 months.
  • Use of any potent inhibitors or inducers or moderate CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study treatment. Note: Moderate CYP3A4 inhibitors are not prohibited
  • Known or severe reaction to pemigatinib, gemcitabine, cisplatin, or their .
  • Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    Pemigatinib

    Drug: Pemigatinib

  • Active comparator
    Gemcitabine + Cisplatin

    Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.

    Drug: Gemcitabine · Drug: Cisplatin

Interventions

  • Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).

    Also known as: INCB054828

  • Gemcitabine 1000 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.

  • Cisplatin 25 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.

06

What researchers measure

Primary outcomes

  1. Randomized Treatment Period: Progression-free Survival (PFS)

    PFS was defined as the time from the date of randomization until the date of disease progression (according to Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] and assessed by an Independent Central Review \[ICR\]) or death, whichever occurs first.

    Time frame: up to 1422 days

  2. Randomized Treatment Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time

    PFS was defined as the time from the date of randomization until the date of disease progression (according to RECIST v1.1 and assessed by an ICR) or death, whichever occurs first. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

    Time frame: up to 1422 days

  3. Transition Period: PFS

    PFS was defined as the time from the date of the first dose of study drug after transition until the earliest date of progressive disease or death due to any cause.

    Time frame: up to 1496 days

  4. Transition Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time

    PFS was defined as the time from the date of the first dose of study drug after transition until the earliest date of progressive disease or death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

    Time frame: up to 1496 days

Secondary outcomes

  1. Randomized Treatment Period: Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

    Time frame: up to 1422 days

  2. Transition Period: ORR

    ORR was defined as the percentage of participants with a best overall response of CR or PR per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

    Time frame: up to 1496 days

  3. Randomized Treatment Period: Overall Survival

    Overall survival was defined as the time from the date of randomization until death due to any cause.

    Time frame: up to 1422 days

  4. Randomized Treatment Period: Kaplan-Meier Estimates of Overall Survival of the Indicated Lengths of Time

    Overall survival was defined as the time from the date of randomization until death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

    Time frame: up to 1422 days

  5. Randomized Treatment Period: Duration of Response (DOR)

    DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.

    Time frame: up to 1422 days

  6. Randomized Treatment Period: Kaplan-Meier Estimates of DOR of the Indicated Lengths of Time

    DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start.

    Time frame: up to 1422 days

  7. Transition Period: DOR

    DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.

    Time frame: up to 1496 days

  8. Transition Period: Kaplan-Meier Estimates of DOR of the Indicated Lengths of Time

    DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start.

    Time frame: up to 1496 days

  9. Randomized Treatment Period: Disease Control Rate (DCR)

    DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or SD per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.

    Time frame: up to 1422 days

  10. Transition Period: DCR

    DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or SD per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.

    Time frame: up to 1496 days

  11. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug for participants who did not transition to pemigatinib. For participants who transitioned to pemigatinib, the end date was 30 days after the last dose date of gemcitabine plus cisplatin or the day before the first dose of pemigatinib after transition, whichever occurred first.

    Time frame: up to 1457 days

  12. Number of Participants With Any Treatment-related TEAE

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug for participants who did not transition to pemigatinib. For participants who transitioned to pemigatinib, the end date was 30 days after the last dose date of gemcitabine plus cisplatin or the day before the first dose of pemigatinib after transition, whichever occurred first.

    Time frame: up to 1457 days

  13. Transition Period: Number of Participants With Any TEAE

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE for the Crossover Evaluable Population was any AE either reported for the first time or for a worsened pre-existing event after the first dose of pemigatinib after switch and until 30 days after the last dose of pemigatinib.

    Time frame: up to 1531 days

  14. Transition Period: Number of Participants With Any Treatment-related TEAE

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE for the Crossover Evaluable Population was any AE either reported for the first time or for a worsened pre-existing event after the first dose of pemigatinib after switch and until 30 days after the last dose of pemigatinib.

    Time frame: up to 1531 days

  15. Randomized Treatment Period: Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-30) Scores at Early Termination

    The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. These include 5 functional scales (physical functioning, role, cognitive functioning, emotional functioning, and social functioning), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status scale, and 6 single items (constipation, diarrhea, sleep, dyspnea, appetite, financial). All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Therefore, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to 1422 days

  16. Randomized Treatment Period: Change From Baseline (CFB) in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Including 21 Questions Specific to the Biliary System (EORTC QLQ-BIL21) at Early Termination

    The EORTC QLQ-BIL21 assessed QoL across 8 scales: eating, jaundice, tiredness, pain, anxiety, treatment side effects, drains, and weight loss. The raw score of each scale is the mean of the item values that contribute to the scale, and the standardized score is a linear transformation of the raw score so that the range is from 0 to 100. A high score for a symptom scale represents a high level of symptomatology/problems. The BIL21 questionnaire was only be administered to participants for whom the questionnaire is validated in that language. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; up to 1422 days

  17. Randomized Treatment Period: Number of Participants With the Indicated Responses on the European Quality of Life 5 Dimensions (3 Levels) Questionnaire (EQ-5D [3L])

    The EQ-5D (3L) is the descriptive system that comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.

    Time frame: Baseline; up to 1422 days

07

Results

Posted Aug 11, 2026
Limitations and caveats
The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision.

Participant flow

Randomized Treatment Period
Participant flow — Randomized Treatment Period
MilestonePemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Started8384
Completed00
Not completed8384
Withdrew: Death5120
Withdrew: Study terminated by sponsor269
Withdrew: Withdrawal by subject512
Withdrew: Disease progression10
Withdrew: Physician decision: worsening of clinical condition01
Withdrew: Transitioned to pemigatinib042
Transition Period
Participant flow — Transition Period
MilestonePemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Started042
Completed00
Not completed042
Withdrew: Death027
Withdrew: Lost to follow-up02
Withdrew: Study terminated by sponsor011
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryRandomized Treatment Period: Progression-free Survival (PFS)

PFS was defined as the time from the date of randomization until the date of disease progression (according to Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] and assessed by an Independent Central Review \[ICR\]) or death, whichever occurs first.

Time frame:
up to 1422 days
Reported as:
Median · months
Randomized Treatment Period: Progression-free Survival (PFS)
monthsPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Randomized Treatment Period: Progression-free Survival (PFS)8.34 (6.51 to 12.22)6.80 (6.05 to 8.25)
Statistical analysis
  • Pemigatinib 13.5 mg QD vs Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD · Log Rank · p = 0.0078 · Hazard ratio (hr): 0.58 · 95% CI 0.39 to 0.87The hazard ratio was estimated using a stratified Cox proportional hazard model using Efron's method accounting for ties in event times. The strata information was based on the IRT randomization data.
PrimaryRandomized Treatment Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time

PFS was defined as the time from the date of randomization until the date of disease progression (according to RECIST v1.1 and assessed by an ICR) or death, whichever occurs first. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Time frame:
up to 1422 days
Reported as:
Number · percent probability
Randomized Treatment Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time
percent probabilityPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
3 months90.0 (81.0 to 94.9)77.8 (66.3 to 85.7)
6 months68.8 (57.1 to 77.9)64.3 (51.9 to 74.3)
9 months44.6 (32.7 to 55.8)26.5 (16.0 to 38.2)
12 months39.1 (27.3 to 50.6)17.1 (8.6 to 27.9)
24 months20.9 (10.8 to 33.2)8.5 (2.2 to 20.2)
36 months11.6 (3.1 to 26.4)8.5 (2.2 to 20.2)
PrimaryTransition Period: PFS

PFS was defined as the time from the date of the first dose of study drug after transition until the earliest date of progressive disease or death due to any cause.

Time frame:
up to 1496 days
Reported as:
Median · months
Transition Period: PFS
monthsGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Transition Period: PFS8.08 (4.44 to 9.89)
PrimaryTransition Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time

PFS was defined as the time from the date of the first dose of study drug after transition until the earliest date of progressive disease or death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Time frame:
up to 1496 days
Reported as:
Number · percent probability
Transition Period: Kaplan-Meier Estimates of PFS of the Indicated Lengths of Time
percent probabilityGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
3 months87.6 (72.6 to 94.6)
6 months62.4 (45.6 to 75.4)
9 months39.7 (24.2 to 54.9)
12 months12.6 (3.6 to 27.3)
24 months4.2 (0.3 to 17.2)
36 months0.0 (NA to NA)
SecondaryRandomized Treatment Period: Objective Response Rate (ORR)

ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

Time frame:
up to 1422 days
Reported as:
Number · percentage of participants
Randomized Treatment Period: Objective Response Rate (ORR)
percentage of participantsPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Randomized Treatment Period: Objective Response Rate (ORR)47.0 (35.93 to 58.26)15.5 (8.51 to 25.01)
Statistical analysis
  • Pemigatinib 13.5 mg QD vs Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 5.57 · 95% CI 2.54 to 12.24The odds ratio (pemigatinib versus gemicitabine plus cisplatin) was calculated using the Cochran-Mantel-Haenszel Test, and the strata information was based on the IRT randomization data.
SecondaryTransition Period: ORR

ORR was defined as the percentage of participants with a best overall response of CR or PR per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.

Time frame:
up to 1496 days
Reported as:
Number · percentage of participants
Transition Period: ORR
percentage of participantsGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Transition Period: ORR38.1 (23.57 to 54.36)
SecondaryRandomized Treatment Period: Overall Survival

Overall survival was defined as the time from the date of randomization until death due to any cause.

Time frame:
up to 1422 days
Reported as:
Median · months
Randomized Treatment Period: Overall Survival
monthsPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Randomized Treatment Period: Overall Survival24.38 (18.63 to 35.91)25.00 (18.66 to 34.20)
Statistical analysis
  • Pemigatinib 13.5 mg QD vs Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD · Cochran-Mantel-Haenszel · p = 0.6581 · Hazard ratio (hr): 1.10 · 95% CI 0.73 to 1.64The hazard ratio (pemigatinib versus gemicitabine plus cisplatin) was estimated using a stratified Cox proportional hazard model using Efron's method accounting for ties in event times. The strata information was based on the IRT randomization data.
SecondaryRandomized Treatment Period: Kaplan-Meier Estimates of Overall Survival of the Indicated Lengths of Time

Overall survival was defined as the time from the date of randomization until death due to any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.

Time frame:
up to 1422 days
Reported as:
Number · percent probability
Randomized Treatment Period: Kaplan-Meier Estimates of Overall Survival of the Indicated Lengths of Time
percent probabilityPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
3 months95.2 (87.7 to 98.2)100.0 (100.0 to 100.0)
6 months89.1 (80.1 to 94.2)97.2 (89.4 to 99.3)
9 months81.7 (71.4 to 88.5)91.7 (82.4 to 96.2)
12 months74.2 (63.3 to 82.4)84.7 (74.1 to 91.2)
24 months51.0 (38.9 to 61.8)55.8 (43.0 to 66.7)
36 months36.6 (24.9 to 48.3)34.1 (22.0 to 46.5)
SecondaryRandomized Treatment Period: Duration of Response (DOR)

DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.

Time frame:
up to 1422 days
Reported as:
Median · months
Randomized Treatment Period: Duration of Response (DOR)
monthsPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Randomized Treatment Period: Duration of Response (DOR)14.19 (8.74 to 24.74)6.31 (4.30 to NA)
Statistical analysis
  • Pemigatinib 13.5 mg QD vs Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD · Cochran-Mantel-Haenszel · p = 0.0526 · Hazard ratio (hr): 0.40 · 95% CI 0.16 to 1.01The hazard ratio (pemigatinib versus gemicitabine plus cisplatin) was estimated using a stratified Cox proportional hazard model using Efron's method accounting for ties in event times. The strata information was based on the IRT randomization data.
SecondaryRandomized Treatment Period: Kaplan-Meier Estimates of DOR of the Indicated Lengths of Time

DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start.

Time frame:
up to 1422 days
Reported as:
Number · percent probability
Randomized Treatment Period: Kaplan-Meier Estimates of DOR of the Indicated Lengths of Time
percent probabilityPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
3 months100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
6 months80.1 (62.8 to 90.0)55.0 (23.2 to 78.3)
9 months66.3 (47.1 to 79.9)45.8 (16.9 to 71.0)
12 months50.4 (31.0 to 67.0)34.4 (9.2 to 61.9)
24 months33.0 (14.0 to 53.6)NA (NA to NA)
36 months24.8 (7.7 to 46.8)NA (NA to NA)
SecondaryTransition Period: DOR

DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.

Time frame:
up to 1496 days
Reported as:
Median · months
Transition Period: DOR
monthsGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Transition Period: DOR6.21 (4.17 to 12.45)
SecondaryTransition Period: Kaplan-Meier Estimates of DOR of the Indicated Lengths of Time

DOR was defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurred first. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. Kaplan-Meier estimates indicate the percent probability of a participant still having a CR or PR at the indicated time after treatment start.

Time frame:
up to 1496 days
Reported as:
Number · percent probability
Transition Period: Kaplan-Meier Estimates of DOR of the Indicated Lengths of Time
percent probabilityGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
3 months100.0 (100.0 to 100.0)
6 months61.4 (33.3 to 80.5)
9 months29.8 (8.6 to 55.0)
12 months29.8 (8.6 to 55.0)
24 months0.0 (NA to NA)
36 months0.0 (NA to NA)
SecondaryRandomized Treatment Period: Disease Control Rate (DCR)

DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or SD per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.

Time frame:
up to 1422 days
Reported as:
Number · percentage of participants
Randomized Treatment Period: Disease Control Rate (DCR)
percentage of participantsPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Randomized Treatment Period: Disease Control Rate (DCR)89.2 (80.41 to 94.92)67.9 (56.78 to 77.64)
Statistical analysis
  • Pemigatinib 13.5 mg QD vs Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD · Cochran-Mantel-Haenszel · p = 0.0007 · Odds ratio (or): 4.10 · 95% CI 1.76 to 9.54The odds ratio (pemigatinib versus gemicitabine plus cisplatin) was calculated using the Cochran-Mantel-Haenszel Test, and the strata information was based on the IRT randomization data.
SecondaryTransition Period: DCR

DCR was defined as the percentage of participants who achieved a best overall response of CR, PR, or SD per RECIST v1.1 as assessed by an ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.

Time frame:
up to 1496 days
Reported as:
Number · percentage of participants
Transition Period: DCR
percentage of participantsGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Transition Period: DCR83.3 (68.64 to 93.03)
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug for participants who did not transition to pemigatinib. For participants who transitioned to pemigatinib, the end date was 30 days after the last dose date of gemcitabine plus cisplatin or the day before the first dose of pemigatinib after transition, whichever occurred first.

Time frame:
up to 1457 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)8373
SecondaryNumber of Participants With Any Treatment-related TEAE

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until 30 days after the last dose of study drug for participants who did not transition to pemigatinib. For participants who transitioned to pemigatinib, the end date was 30 days after the last dose date of gemcitabine plus cisplatin or the day before the first dose of pemigatinib after transition, whichever occurred first.

Time frame:
up to 1457 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-related TEAE
ParticipantsPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Number of Participants With Any Treatment-related TEAE8070
SecondaryTransition Period: Number of Participants With Any TEAE

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE for the Crossover Evaluable Population was any AE either reported for the first time or for a worsened pre-existing event after the first dose of pemigatinib after switch and until 30 days after the last dose of pemigatinib.

Time frame:
up to 1531 days
Reported as:
Count of participants · Participants
Transition Period: Number of Participants With Any TEAE
ParticipantsGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Transition Period: Number of Participants With Any TEAE42
SecondaryTransition Period: Number of Participants With Any Treatment-related TEAE

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE for the Crossover Evaluable Population was any AE either reported for the first time or for a worsened pre-existing event after the first dose of pemigatinib after switch and until 30 days after the last dose of pemigatinib.

Time frame:
up to 1531 days
Reported as:
Count of participants · Participants
Transition Period: Number of Participants With Any Treatment-related TEAE
ParticipantsGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Transition Period: Number of Participants With Any Treatment-related TEAE41
SecondaryRandomized Treatment Period: Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-30) Scores at Early Termination

The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. These include 5 functional scales (physical functioning, role, cognitive functioning, emotional functioning, and social functioning), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status scale, and 6 single items (constipation, diarrhea, sleep, dyspnea, appetite, financial). All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Therefore, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to 1422 days
Reported as:
Mean · scores on a scale
Randomized Treatment Period: Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-30) Scores at Early Termination
scores on a scalePemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Baseline, Appetite loss17.1 ± 27.5622.4 ± 31.46
CFB at Early Termination, Appetite loss10.2 ± 26.71-3.7 ± 32.64
Baseline, Constipation12.9 ± 18.7514.9 ± 23.42
CFB at Early Termination, Constipation11.8 ± 27.060.9 ± 30.33
Baseline, Cognitive functioning86.4 ± 15.1691.2 ± 13.15
CFB at Early Termination, Cognitive functioning-5.4 ± 18.05-1.9 ± 23.14
Baseline, Diarrhea11.1 ± 22.366.5 ± 15.61
CFB at Early Termination, Diarrhea0.5 ± 20.460.9 ± 12.56
Baseline, Dyspnea16.9 ± 24.2214.9 ± 21.15
CFB at Early Termination, Dyspnea2.2 ± 24.058.3 ± 26.87
Baseline, Emotional functioning75.9 ± 19.2178.2 ± 20.15
CFB at Early Termination, Emotional functioning-5.6 ± 20.90-9.3 ± 19.60
Baseline, Fatigue31.0 ± 25.3826.2 ± 22.53
CFB at Early Termination, Fatigue6.8 ± 20.9410.6 ± 22.16
Baseline, Financial difficulties14.0 ± 24.6420.4 ± 31.76
CFB at Early Termination, Financial difficulties8.1 ± 29.377.4 ± 26.56
Baseline, Global health status/QoL66.7 ± 22.8267.5 ± 20.00
CFB at Early Termination, Global health status/QoL-8.3 ± 20.36-6.0 ± 22.85
Baseline, Insomnia30.5 ± 31.2724.9 ± 28.63
CFB at Early Termination, Insomnia-6.5 ± 29.47-3.7 ± 23.61
Baseline, Nausea and vomiting8.6 ± 16.2711.1 ± 21.94
CFB at Early Termination, Nausea and vomiting-1.9 ± 18.131.4 ± 21.91
Baseline, Pain24.6 ± 28.5620.1 ± 23.31
CFB at Early Termination, Pain6.6 ± 29.072.3 ± 22.24
Baseline, Physical functioning82.3 ± 21.4582.7 ± 19.21
CFB at Early Termination, Physical functioning-11.6 ± 20.36-5.6 ± 22.79
Baseline, Role functioning76.7 ± 31.1479.1 ± 24.51
CFB at Early Termination, Role functioning-18.0 ± 31.26-13.0 ± 26.16
Baseline, Social functioning77.4 ± 26.0077.4 ± 24.91
CFB at Early termination, Social functioning-12.4 ± 27.65-11.1 ± 21.82
SecondaryRandomized Treatment Period: Change From Baseline (CFB) in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Including 21 Questions Specific to the Biliary System (EORTC QLQ-BIL21) at Early Termination

The EORTC QLQ-BIL21 assessed QoL across 8 scales: eating, jaundice, tiredness, pain, anxiety, treatment side effects, drains, and weight loss. The raw score of each scale is the mean of the item values that contribute to the scale, and the standardized score is a linear transformation of the raw score so that the range is from 0 to 100. A high score for a symptom scale represents a high level of symptomatology/problems. The BIL21 questionnaire was only be administered to participants for whom the questionnaire is validated in that language. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; up to 1422 days
Reported as:
Mean · scores on a scale
Randomized Treatment Period: Change From Baseline (CFB) in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Including 21 Questions Specific to the Biliary System (EORTC QLQ-BIL21) at Early Termination
scores on a scalePemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Baseline, Anxiety35.9 ± 24.7836.1 ± 25.83
CFB at Early Termination, Anxiety5.7 ± 24.430.8 ± 18.50
Baseline, Drains2.3 ± 10.142.9 ± 12.92
CFB at Early Termination, Drains3.0 ± 17.157.8 ± 27.24
Baseline, Eating14.9 ± 17.3417.5 ± 19.44
CFB at Early Termination, Eating12.2 ± 19.683.9 ± 21.22
Baseline, Jaundice5.6 ± 10.405.6 ± 10.61
CFB at Early Termination, Jaundice-1.7 ± 9.991.5 ± 10.67
Baseline, Pain22.5 ± 19.9718.8 ± 18.62
CFB at Early Termination, Pain-7.6 ± 20.315.9 ± 15.30
Baseline, Treatment side effects14.4 ± 25.3313.0 ± 25.53
CFB at Early Termination, Treatment side effects30.5 ± 36.5611.5 ± 30.06
Baseline, Tiredness34.8 ± 31.0933.7 ± 32.32
CFB at Early Termination, Tiredness6.9 ± 26.994.0 ± 28.87
Baseline, Weight loss18.7 ± 25.2621.0 ± 27.81
CFB at Early Termination, Weight loss2.9 ± 22.76-9.8 ± 33.36
SecondaryRandomized Treatment Period: Number of Participants With the Indicated Responses on the European Quality of Life 5 Dimensions (3 Levels) Questionnaire (EQ-5D [3L])

The EQ-5D (3L) is the descriptive system that comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.

Time frame:
Baseline; up to 1422 days
Reported as:
Count of participants · Participants
Randomized Treatment Period: Number of Participants With the Indicated Responses on the European Quality of Life 5 Dimensions (3 Levels) Questionnaire (EQ-5D [3L])
ParticipantsPemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QD
Baseline, Anxiety/Depression; no problems21
Baseline, Anxiety/Depression; some problems6052
Baseline, Anxiety/Depression; extreme problems1815
Early Termination, Anxiety/Depression; no problems30
Early Termination, Anxiety/Depression; some problems3626
Early Termination, Anxiety/Depression; extreme problems2411
Baseline, Mobility; no problems20
Baseline, Mobility; some problems7465
Baseline, Mobility; extreme problems53
Early Termination, Mobility; no problems11
Early Termination, Mobility; some problems4733
Early Termination, Mobility; extreme problems153
Baseline, Pain/Discomfort; no problems53
Baseline, Pain/Discomfort; some problems5243
Baseline, Pain/Discomfort; extreme problems2322
Early Termination, Pain/Discomfort; no problems63
Early Termination, Pain/Discomfort; some problems2822
Early Termination, Pain/Discomfort; extreme problems2812
Baseline, Self-care; no problems43
Baseline, Self-care; some problems4136
Baseline, Self-care; extreme problems3528
Early Termination; Self-care; no problems20
Early Termination; Self-care; some problems4214
Early Termination; Self-care; extreme problems1923
Baseline, Usual Activities; no problems21
Baseline, Usual Activities; some problems3329
Baseline, Usual Activities; extreme problems4638
Early Termination, Usual Activities; no problems32
Early Termination, Usual Activities; some problems3017
Early Termination, Usual Activities; extreme problems3018

Adverse events

Collected over up to approximately 6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Period: Pemigatinib 13.5 mg QD51/83 (61.4%)23/83 (27.7%)83/83 (100%)
Randomized Period: Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^247/84 (56%)17/73 (23.3%)72/73 (98.6%)
Transition Period: Pemigatinib 13.5 mg QD27/42 (64.3%)9/42 (21.4%)42/42 (100%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventRandomized Period: Pemigatinib 13.5 mg QDRandomized Period: Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2Transition Period: Pemigatinib 13.5 mg QD
CholangitisHepatobiliary disorders1/832/732/42
SepsisInfections and infestations3/830/731/42
Platelet count decreasedInvestigations0/832/730/42
Jaundice cholestaticHepatobiliary disorders2/830/730/42
Abdominal painGastrointestinal disorders1/830/731/42
AnaemiaBlood and lymphatic system disorders0/831/731/42
AscitesGastrointestinal disorders0/831/731/42
Back painMusculoskeletal and connective tissue disorders0/831/731/42
MalaiseGeneral disorders0/831/731/42
NauseaGastrointestinal disorders0/830/731/42
Most frequent other events
Showing 10 of 87
Most frequent other events
EventRandomized Period: Pemigatinib 13.5 mg QDRandomized Period: Gemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2Transition Period: Pemigatinib 13.5 mg QD
HyperphosphataemiaMetabolism and nutrition disorders68/832/7337/42
AlopeciaSkin and subcutaneous tissue disorders47/8313/7321/42
AnaemiaBlood and lymphatic system disorders12/8337/735/42
NauseaGastrointestinal disorders17/8336/736/42
StomatitisGastrointestinal disorders38/8312/7320/42
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders39/832/7316/42
ConstipationGastrointestinal disorders37/8326/7313/42
DiarrhoeaGastrointestinal disorders37/8312/7313/42
FatigueGeneral disorders17/8331/7310/42
DysgeusiaNervous system disorders31/838/7315/42

Baseline characteristics

Age, Customized
Age, Customized(years)Pemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QDTotal
Mean59.4 ± 13.0557.2 ± 12.4558.3 ± 12.76
Sex: Female, Male
Sex: Female, Male(Participants)Pemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QDTotal
Female465197
Male373370
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QDTotal
White6057117
Black or African American538
Asian111728
Not Reported6511
Captured as "Hispanic" in the Database101
Asian - Indian011
Egyptian011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pemigatinib 13.5 mg QDGemcitabine 1000 mg/m^2 Plus Cisplatin 25 mg/m^2 to Pemigatinib 13.5 mg QDTotal
Hispanic or Latino437
Not Hispanic or Latino6661127
Not Reported101424
Unknown202
Captured as "Other" in Database167
08

Study locations

215 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Marin Cancer Care
    Greenbrae, California 94904, United States
  • UC Irvine Medical Center
    Orange, California 92868-3201, United States
  • Georgetown University-Lombardi Comprehensive Cancer Center
    Washington D.C., District of Columbia 20007, United States
  • Mayo Clinic-Florida
    Jacksonville, Florida 32224, United States
  • Mount Sinai Medical Center Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637-1447, United States
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
  • University of Iowa Hospital and Clinics
    Iowa City, Iowa 52242, United States
  • The University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Ochsner Clinic Foundation Ocf Ochsner Cancer Institute Oci
    New Orleans, Louisiana 70121, United States
  • Johns Hopkins Oncology Center
    Baltimore, Maryland 21287, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Barbara Ann Karmanos Cancer Hospital
    Detroit, Michigan 48201, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Karmanos Cancer Institute
    Farmington Hills, Michigan 48334, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Comprehensive Cancer Centers of Nevada-Twain
    Las Vegas, Nevada 89169, United States
  • Summit Medical Group
    Florham Park, New Jersey 07932, United States
  • Icahn School of Medicine At Mount Sinai
    New York, New York 10029, United States
  • White Plains Hospital
    White Plains, New York 10601, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Providence Portland Med. Ctr
    Portland, Oregon 97213, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Greenville Hospital System University Medical Center Institute For Translational Oncology Research
    Greenville, South Carolina 29605, United States
  • Baylor Scott and White Research Institute
    Dallas, Texas 75246, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • Riverside Regional Medical Center
    Newport News, Virginia 23601, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23229, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • West Virginia University Cancer Institute
    Morgantown, West Virginia 26506, United States
  • Aurora Research Institute
    Wauwatosa, Wisconsin 53226, United States
  • Landeskrankenhaus Universitatsklinikum Graz
    Graz, 08036, Austria
  • Innsbruck University Hospital
    Innsbruck, A-6020, Austria
  • Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz
    Linz, 04010, Austria
  • Salzburger Universitatsklinikum
    Salzburg, 05020, Austria
  • Landeskrankenhaus Steyr
    Steyr, 04400, Austria
  • Allgemeines Krankenhaus Der Stadt Wien
    Vienna, 01090, Austria
  • Ulb Hospital Erasme
    Brussels, 01070, Belgium
  • Universitair Ziekenhuis Brussel
    Brussels, 01090, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 09000, Belgium
  • Hospital de Jolimont
    Haine-st-paul, 07100, Belgium
  • Az Groeninge Campus Kennedylaan
    Kortrijk, 08500, Belgium
  • Universitaire Ziekenhuis Leuven - Gasthuisberg
    Leuven, 03000, Belgium
  • Chu Ucl Namur University Hospital Mont-Godinne
    Yvoir, 05530, Belgium
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Cancercare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Nova Scotia Health Authority/Qeii Health Sciences Centre
    Halifax, Nova Scotia B3H 4K4, Canada
  • Princess Margaret Cancer Center
    Toronto, Ontario MG5 2M9, Canada
  • McGill University Health Centre Research Institute
    Montreal, Quebec H4A 3J1, Canada
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • West China Hospital Sichuan University
    Chengdu, 610041, China
  • Fujian Cancer Hospital
    Fuzhou, 350005, China
  • Sun Yat-Sen Memorial Hospital Sun Yat-Sen University
    Guangdong, 510000, China
  • Sun Yat-Sen Memorial Hospital Sun Yat-Sen University
    Guangzhou, 510000, China
  • Shulan Hangzhou Hospital Co Ltd
    Hangzhou, 310000, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, 310009, China
  • Heilongjiang Province Cancer Hospital
    Harbin, 150081, China
  • University of Science and Technology of China-First Affiliated Hospital (Anhui Provincial Hospital)
    Hefei, 230001, China
  • Kunming 1St People'S Hospital
    Kunming, 650032, China
  • Jiangsu Province Hospital
    Nanjing, 210029, China
  • The Affiliated Hospital of Qingdao University
    Shandong, 266071, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, 200092, China
  • Xinhua Hospital
    Shanghai, 200092, China
  • Sichuan Cancer Hospital
    Sichuan, 610041, China
  • Tianjin Medical University Cancer Institute Hospital
    Tianjin, 300060, China
  • Tongji Hospital Huazhong University of Science and Technology
    Wuhan, 430030, China
  • Hubei Cancer Hospital
    Wuhan, 430079, China
  • Northern Jiangsu Peoples Hospital
    Yangzhou, 225001, China
  • Herlev Og Gentofte Hospital
    Herlev, 02730, Denmark
  • Docrates Cancer Center
    Helsinki, 00180, Finland
  • Helsinki University Central Hospital
    Helsinki, 00290, Finland
  • Tampere University Hospital
    Tampere, 33521, Finland
  • Institut Sainte Catherine
    Avignon, 84918, France
  • Chu Besancon Hospital Jean Minjoz
    Besançon, 25030, France
  • Institut Bergonie
    Bordeaux, 33076, France
  • Hopital Beaujon
    Clichy, 92110, France
  • Chu de Limoges - Hospital Dupuytren
    Limoges, 87042, France
  • Hopital Prive Jean Mermoz
    Lyon, 69373, France
  • Chu Hopital de La Timone
    Marseille, 13385, France
  • Centre Hospitalier Universitaire de Nantes
    Nantes, 44000, France
  • Centre Antoine Laccassagne
    Nice, 06189, France
  • Hospital Universitaire Pitie-Salpetriere
    Paris, 75013, France
  • Hopital Europeen Georges Pompidou (Hegp)
    Paris, 75015, France
  • Centre Hospitalier Universitaire de Bordeaux - Hospital Haut-Leveque
    Pessac, 336600, France
  • Hospital de La Miletrie
    Poitiers, 86021, France
  • Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume
    Rouen, 76031, France
  • University Hospital of Saint Etienne
    Saint-Etienne, 42055, France
  • Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau
    Saint-Herblain, 44800, France
  • Chu Toulouse Hopital Rangueil
    Toulouse, 31059, France
  • Chu Vandoeuvre-Les-Nancy Hopital Brabois
    Vandœuvre-lès-Nancy, 54511, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • University Medical Center Rwth Aachen
    Aachen, 52074, Germany
  • Charite - Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Charite Universitaetsmedizin Berlin - Campus Charite Mitte
    Berlin, 13353, Germany

Showing the first 100 of 215 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bekaii-Saab TS, Melisi D, Wilmink H, Garufi C, Tran N, Tortora G, De Braud F, Frodin JE, Lonardi S, Lin E, Babiker H, Lin B, Fornaro L, Munoz Martin A, Bridgewater J, Knox JJ, De Vos-Geelen J, Scott-Brown M, Veronese L, Ioannidis S, Gilmartin A, Janik JE, Guo Y, Furuse J, Ioka T, Rimassa L, Vogel A. Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial. J Clin Oncol. 2026 Jun 1:JCO2600788. doi: 10.1200/JCO-26-00788. Online ahead of print. PubMed 42223137 ↗
  • Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Feliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020 Oct;16(30):2385-2399. doi: 10.2217/fon-2020-0429. Epub 2020 Jul 17. PubMed 32677452 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Jul 2025, 73 months.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2018
First posted
Sep 4, 2018
StartActual
Jun 3, 2019
Primary completionActual
Jul 7, 2025
CompletionActual
Jul 7, 2025
Results first posted
Aug 11, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03656536
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Sep 4, 2018
Start date
Jun 3, 2019
Primary completion
Jul 7, 2025
Completion
Jul 7, 2025
Results posted
Aug 11, 2026
Last update
Aug 11, 2026

Study contacts

Peter Langmuir, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion